Madrigal Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030

Updated on 02/05/2023

Stock Rating
4
Price Target
$175.00
Consensus
Outperform
Downside
-37.45%
Analysts
7
Stock Rating
4
Downside
-37.45%
Analysts
7
Price Target
$175.00

Madrigal Pharmaceuticals Stock Forecast and Price Target

According to seven experts, who recently provided their 2023 price targets for Madrigal Pharmaceuticals, the average price target is $175.00, with a high estimate of $203.00 and a low estimate of $131.00. That is a potential downside of approximately -37.45% from the last closing price of $279.79 on February, 2023.

$175.00

-37.45% Downside

Outperform
Outperform

Madrigal Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030

In the last two years, Price for Madrigal Pharmaceuticals has grown by 100.00%, going from $0.00 to $0.00. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $276.63 – an increase of 100.00%. Over the next nine years, experts anticipate that Fair Value growth for Madrigal Pharmaceuticals will be 100.00%.

2022 Fair Value Forecast
$276.63
2023 Fair Value Forecast
$307.93
2024 Fair Value Forecast
$342.39
2025 Fair Value Forecast
$380.71
2026 Fair Value Forecast
$423.31
2027 Fair Value Forecast
$470.67
2028 Fair Value Forecast
$523.34
2029 Fair Value Forecast
$581.91
2030 Fair Value Forecast
$647.02

Madrigal Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030

Madrigal Pharmaceuticals Dividend per Share Forecast for 2023 - 2025 - 2030

Madrigal Pharmaceuticals Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last two years, Madrigal Pharmaceuticals's Free Cash Flow has grown, increasing from $-41.79M to $-184.25M – an increase of 340.89%. For the following year, the 0 analysts predict that Madrigal Pharmaceuticals's Free Cash Flow will drop by 34.05%, reaching $-121.51M. In 2030, the professionals' prediction is that MDGL's Free Cash Flow will decrease by 26.48%, reaching $-135.47M.

2022 FCF Forecast
$-121512875.00
2023 FCF Forecast
$-106846270.99
2024 FCF Forecast
$-125027944.77
2025 FCF Forecast
$-146207678.61
2026 FCF Forecast
$-138751087.00
2027 FCF Forecast
$-127808251.27
2028 FCF Forecast
$-127569675.87
2029 FCF Forecast
$-133573955.28
2030 FCF Forecast
$-135466252.98

Madrigal Pharmaceuticals Net Income Forecast for 2023 - 2025 - 2030

In the last two years, Madrigal Pharmaceuticals's Net Income has increased by 188.09%, going from $-83.95M to $-241.85M. 0 analysts predict Madrigal Pharmaceuticals's Net Income will decrease by 30.42% in the next year, reaching $-168.29M. By 2030, professionals predict that Madrigal Pharmaceuticals's Net Income will decrease by 24.31%, to $-183.06M.

2022 NI Forecast
$-168287291.67
2023 NI Forecast
$-150807851.64
2024 NI Forecast
$-170372656.92
2025 NI Forecast
$-195258423.01
2026 NI Forecast
$-187031534.79
2027 NI Forecast
$-174668750.34
2028 NI Forecast
$-173929319.30
2029 NI Forecast
$-180834313.27
2030 NI Forecast
$-183058575.33

Madrigal Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030

Madrigal Pharmaceuticals's EBITDA has increased by 155.20% In the last two years, going from $-94.86M to $-242.08M. In the following year, the 0 analysts surveyed believe that Madrigal Pharmaceuticals's EBITDA will decrease by 27.88%, reaching $-174.59M. According to professionals, by 2030, Madrigal Pharmaceuticals's EBITDA will have decreased by 22.64%, falling down to $-187.27M.

2022 EBITDA Forecast
$-174588096.00
2023 EBITDA Forecast
$-157036172.75
2024 EBITDA Forecast
$-175367528.65
2025 EBITDA Forecast
$-198393285.16
2026 EBITDA Forecast
$-191198222.02
2027 EBITDA Forecast
$-179535130.47
2028 EBITDA Forecast
$-178727222.39
2029 EBITDA Forecast
$-185107784.23
2030 EBITDA Forecast
$-187267375.04

Madrigal Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030

In the last two years, Madrigal Pharmaceuticals's EBIT has grown, increasing from $-94.97M to $-242.48M – a growth of 155.32%. The next year, 0 experts forecast that Madrigal Pharmaceuticals's EBIT will decrease by 27.86%, reaching $-174.92M. In 2030, professionals predict that Madrigal Pharmaceuticals's EBIT will decrease by 22.63%, reaching $-187.61M.

2022 EBIT Forecast
$-174916989.33
2023 EBIT Forecast
$-157314509.64
2024 EBIT Forecast
$-175694088.18
2025 EBIT Forecast
$-198745152.55
2026 EBIT Forecast
$-191543953.19
2027 EBIT Forecast
$-179859772.05
2028 EBIT Forecast
$-179056398.40
2029 EBIT Forecast
$-185448711.82
2030 EBIT Forecast
$-187612280.13

Madrigal Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030

In the last two years, EPS for Madrigal Pharmaceuticals has grown by 168.44%, going from $-5.45 to $-14.63. According to 0 analysts, Madrigal Pharmaceuticals's EPS will fall by 26.48% in the next year, reaching $-10.76. Professionals believe that By 2030, Madrigal Pharmaceuticals's EPS will fall to $-11.47 – a 21.61% decrease from its current value.

2022 EPS Forecast
$-10.76
2023 EPS Forecast
$-9.58
2024 EPS Forecast
$-10.78
2025 EPS Forecast
$-12.12
2026 EPS Forecast
$-11.72
2027 EPS Forecast
$-10.98
2028 EPS Forecast
$-10.95
2029 EPS Forecast
$-11.33
2030 EPS Forecast
$-11.47